恩替卡韦联合红外肝病治疗仪治疗乙型肝炎肝硬化患者疗效研究*

doi:10.3969/j.issn.1672-5069.2025.06.020

摘要/Abstract

摘要： 目的探讨恩替卡韦联合红外肝病治疗仪治疗乙型肝炎肝硬化患者的近期效果。方法 2021年1月～2024年1月我院诊治的84例乙型肝炎肝硬化患者,被随机分为对照组42例,接受恩替卡韦治疗,和观察组42例,接受恩替卡韦联合生物信息红外肝病治疗仪治疗,两组均观察3个月。采用荧光定量PCR法检测血清HBV DNA载量,采用ELISA法检测血清HBsAg和HBeAg,采用ELISA法检测血清转化生长因子 β1(TGF-β1) 、白介素-6(IL-6)和肿瘤坏死因子-α(TNF-α),采用放射免疫法检测血清透明质酸、层粘连蛋白、Ⅲ型前胶原和Ⅳ型胶原,使用超声检测脾静脉内径、门静脉内径和门静脉血流流速。结果观察组血清透明质酸、Ⅲ型前胶原和Ⅳ型胶原水平分别为(102.2±10.3)mg/L、(114.2±11.5)ng/mL和(71.2±7.3)ng/mL,均显著低于对照组【分别为(134.0±11.5)mg/L、(152.7±13.8)ng/mL和(89.1±9.2)ng/mL,P＜0.05】;血清TGF-β1、IL-6和TNF-α水平分别为(20.3±3.9)ng/mL、(17.0±2.6)ng/mL和(21.4±3.1)ng/mL,均显著低于对照组【分别为(31.4±4.1)ng/mL、(24.3±3.0)ng/mL和(33.5±4.2)ng/mL,P＜0.05】;两组肝功能指标、血清HBV标记物、病毒载量和门脉指标比较,无显著性差异(P>0.05)。结论采用恩替卡韦联合肝病治疗仪治疗乙型肝炎肝硬化患者可短期改善血清肝纤维化指标,可能与改善了细胞因子代谢有关。

关键词: 肝硬化, 乙型肝炎, 恩替卡韦, 红外肝病治疗仪, 治疗

Abstract: Objective The aim of this study was to investigate entecavir (ETV) antiviral treatment with daily outcutaneous irradiation of infrared ray in patients with hepatitis B-induced liver cirrhosis (LC). Methods 84 patients with LC due to hepatitis B viral infection were encountered in our hospital between January 2021 and January 2024, and were randomly assigned to receive oral ETV (control, n＝42) or ETV with daily outcutaneous irradiation of infrared ray by a bio-informational infrared liver disease therapist (observation, n＝42). All patients were followed-up for three months. Serum HBV markers and HBV DNA loads were routinely detected. Serum hyaluronic acid (HA), laminin (LN), type Ⅲ procollagen (PⅢ-P) and collage type Ⅳ(Ⅳ-C) levels were detected by RIA. Serum transforming growth factor beta 1 (TGF-β1) , interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) levels were assayed by ELISA. Splenic vein diameter (SVD) and portal vein diameter (PVD), and portal vein flow velocity (PVFV) were determined by ultrasonography. Results By end of three month observation, serum HA, PⅢ-P and Ⅳ-C levels in the observation group were(102.2±10.3)mg/L, (114.2±11.5)ng/mL and (71.2±7.3)ng/mL, all significantly lower than [(134.0±11.5)mg/L, (152.7±13.8)ng/mL and (89.1±9.2)ng/mL, respectively, P＜0.05] in the control; serum TGF-β1, IL-6 and TNF-α levels were (20.3±3.9)ng/mL, (17.0±2.6)ng/mL and (21.4±3.1)ng/mL, all significantly lower than [(31.4±4.1)ng/mL, (24.3±3.0)ng/mL and (33.5±4.2)ng/mL, respectively, P＜0.05] in the control group; there were no significant differences as respect to liver function index, serum HBsAg and HBeAg, serum HBV DNA loads, and portal vein parameters between the two groups (P>0.05). Conclusion Entecavir antiviral treatment with auxiliary infrared ray irradiation could inhibit liver fibrosis progression, which might be related to modulation of cytokine metabolism.

Key words: Liver cirrhosis, Hepatitis B, Entecavir, Bio-informational infrared iiver disease therapist, Therapy

黄晓黎, 沈杰. 恩替卡韦联合红外肝病治疗仪治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 878-881.

Huang Xiaoli, Shen Jie. Entecavir antiviral treatment with daily outcutaneous irradiation of infrared ray in patients with hepatitis B-induced liver cirrhosis[J]. Journal of Practical Hepatology, 2025, 28(6): 878-881.

参考文献

[1] Shoraka S, Mohebbi SR, Hosseini SM, et al. Identification of plasma lncRNA-ATB levels in hepatitis B virus-related cirrhosis and non-cirrhotic chronic hepatitis B patients. Virus Res, 2021, 303:198503.
[2] Pereira GH, Peixoto HR, Giusti ML,et al. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study. Braz J Infect Dis, 2022, 26(5):102697.
[3] Lamatsch S, Sittner R, Tacke F,et al. Novel drug discovery strategies for the treatment of decompensated cirrhosis. Expert Opin Drug Discov, 2022, 17(3):273-282.
[4] Farina E, Loglio A, Tosetti G,et al. Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated withtenofovir or entecavir for 11 years. Aliment Pharmacol Ther, 2023, 57(12):1407-1416.
[5] Kaibori M, Kosaka H, Matsui K,et al. Near-infrared fluorescence imaging and photodynamic therapy for liver tumors. Front Oncol, 2021,11:638327.
[6] Lu H, Zheng C, Xiong B,et al. TACE versus TACE+entecavir versus TACE+tenofovir in the treatment of HBV associated hepatocellular carcinoma. BMC Cancer, 2023, 23(1):235.
[7] 中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志,2020,23(1):后插9-后插32.
[8] Villanueva C, Albillos A, Genescà J,et al. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. J Hepatol, 2021, 75(3):589-599.
[9] Kazmi SS, Naz Awan A, Khan A,et al. Molecular dynamics simulation of entecavir-silver nanoparticles at different biological pH. Pak J Pharm Sci, 2022, 35(4):973-983.
[10] Huang CW, Yang CT, Su PY,et al. Chronic hepatitis B relapse rates after cessation of tenofovir alafenamide and entecavir therapy. Biomedicines, 2023, 11(3):752.
[11] Chen CH, Peng CY, Hu TH,et al. Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B. Aliment Pharmacol Ther, 2023, 58(3):334-345.
[12] Colombatto P, Palmisano E, Ricco G,et al. Different inetics of HBV-DNA and HBsAg in HCVcoinfected patients during DAAs therapy. J Clin Med, 2022, 11(5):1406.
[13] Tseng TN, Jeng WJ, Hu TH,et al. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. J Antimicrob Chemother,2023, 78(2):436-439.
[14] Shao J, Liu Y, Liu LM,et al. Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients. J Infect Dev Ctries, 2021, 15(1):131-140.
[15] Gohar M, Rehman IU, Ullah A,et al. Phylogenetic analysis and emerging drug resistance against different nucleoside analogues in hepatitis B virus positive patients. Microorganisms, 2023, 11(11):2622.
[16] Deng H, Shang W, Lu G,et al. Targeted and multifunctional technology for identification between hepatocellular carcinoma and liver cirrhosis. ACSAppl Mater Interfaces, 2019, 11(16):14526-14537.
[17] Wakiyama H, Kato T, Furusawa A,et al. Near infrared photoimmunotherapy of cancer; possible clinical applications. Nanophotonics, 2021, 10(12):3135-3151.
[18] Wan L, Hu C, Wang F,et al. Evaluation of the efficacy of Biejia decoction pill combined with entecavir in the treatment of hepatitis B liver fibrosis/cirrhosis by VCTE. Sci Rep, 2023, 13(1):19616.
[19] Nasser N, Tonnerre P, Mansouri A, et al. Hepatitis-B virus: replication cycle, targets, and antiviral approaches. Curr Opin Virol,2023,63:101360.
[20] Karagiannakis DS, Voulgaris T, Markakis G,et al. Spleen stiffness can predict liver decompensation and survival in patients with cirrhosis. J Gastroenterol Hepatol, 2023,38(2):283-289.

恩替卡韦联合红外肝病治疗仪治疗乙型肝炎肝硬化患者疗效研究^*

Entecavir antiviral treatment with daily outcutaneous irradiation of infrared ray in patients with hepatitis B-induced liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	姚羽, 宁波. 肝硬化门静脉血栓形成机制、自发性再通和抗凝治疗研究进展^*[J]. 实用肝脏病杂志, 2025, 28(6): 801-804.
[2]	李思思, 姜艳贞, 付兆媛. 中西医结合治疗肝纤维化研究进展与思考^*[J]. 实用肝脏病杂志, 2025, 28(6): 805-808.
[3]	华琪, 刘琼, 陈琦. 艾米替诺福韦治疗经恩替卡韦治疗的低病毒血症的慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 818-821.
[4]	蒋婵娟, 邵靖渊, 徐林. 艾尔巴韦/格拉瑞韦治疗慢性肾病合并慢性丙型肝炎患者疗效和安全性研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 822-825.
[5]	王超杰, 谢群, 姜海, 周宝勤, 杨亮. 3D方案治疗初始治疗的基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 826-829.
[6]	李卉, 陶娅, 胥勋梅, 王金帆. 利拉鲁肽治疗NAFLD合并T2DM患者疗效及其对外周血单个核细胞NLRP3、Caspase-1和ASC水平的影响^*[J]. 实用肝脏病杂志, 2025, 28(6): 830-833.
[7]	郑慧慧, 王玉蓉, 徐婷. 血脂康联合阿托伐他汀治疗非酒精性脂肪性肝病合并高脂血症患者效果研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 834-837.
[8]	王美玲, 李洁, 刘娟, 孙婷婷. 司美格鲁肽联合非诺贝特治疗2型糖尿病合并非酒精性脂肪性肝病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 838-841.
[9]	高海娜, 梁盼, 高琳辉, 朱立影, 宋媛, 李印肖, 刘阳. 艾塞那肽联合二甲双胍治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 842-845.
[10]	陈晓玲, 张盼盼, 付玉芳, 王静. 司美格鲁肽联合化痰祛瘀通络方治疗NAFLD合并T2DM患者临床疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 846-849.
[11]	田巍巍, 孙佳琦, 陈恳, 黄亚彬, 李锋, 冯海娟. 标准免疫抑制疗法联合甘草酸二铵治疗自身免疫性肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 854-857.
[12]	彭冬梅, 王栋, 谢晓卒. 腹水多形核细胞计数联合全身免疫炎症指数和血清CRP/ALB比值诊断失代偿期肝硬化患者并发自发性细菌性腹膜炎价值研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 874-877.
[13]	陆涛, 李家国, 李士伟, 姚豪杰. 脾切除术联合门奇静脉断流术治疗乙型肝炎肝硬化患者门静脉血栓形成影响因素分析^*[J]. 实用肝脏病杂志, 2025, 28(6): 882-885.
[14]	陈杉杉, 司晓闯, 朱家宝, 谢淑慧, 吴静, 吴彬彬, 徐艳青, 梁燕楼, 王子弦, 孙亚楠. 多种无创诊断指标评估原发性胆汁性胆管炎患者肝硬化价值研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 886-889.
[15]	杨兰, 许诗杰, 包华鑫. 肝细胞癌患者TACE术后血清FGFR1、VEGFA和IRX5水平变化及其与疗效的关系研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 890-893.